Fulcrum Therapeutics, Inc. (FULC)
| Market Cap | 451.77M +47.3% |
| Revenue (ttm) | n/a |
| Net Income | -76.12M |
| EPS | -1.14 |
| Shares Out | 66.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 325,992 |
| Open | 6.76 |
| Previous Close | 6.76 |
| Day's Range | 6.74 - 7.00 |
| 52-Week Range | 5.88 - 15.74 |
| Beta | 3.01 |
| Analysts | Buy |
| Price Target | 18.90 (+178.76%) |
| Earnings Date | Apr 27, 2026 |
About FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for FULC stock is "Buy." The 12-month stock price target is $18.9, which is an increase of 178.76% from the latest price.
News
Fulcrum Therapeutics price target raised to $8 from $7 at BofA
BofA raised the firm’s price target on Fulcrum Therapeutics (FULC) to $8 from $7 and keeps an Underperform rating on the shares. The firm updated the company’s model post the…
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of ...
Fulcrum Therapeutics Proxy statement: Proxy filing
Fulcrum Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Fulcrum Therapeutics Proxy statement: Proxy filing
Fulcrum Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Fulcrum Therapeutics Earnings Call Transcript: Q1 2026
Positive phase I-B data for pociredir in sickle cell disease showed robust HbF increases and reduced VOCs, with strong safety and a solid cash runway into 2029. A registration-enabling trial is planned for the second half of 2026, pending FDA feedback.
Fulcrum Therapeutics Earnings release: Q1 2026
Fulcrum Therapeutics released its Q1 2026 earnings on April 27, 2026, summarizing the period's financial results.
Fulcrum Therapeutics Quarterly report: Q1 2026
Fulcrum Therapeutics has published its Q1 2026 quarterly earnings report on April 27, 2026.
Fulcrum Therapeutics reports Q1 EPS (25c), consensus (30c)
As of March 31, cash, cash equivalents, and marketable securities were $333.3M, compared to $352.3M as of December 31, 2025. The decrease of $19M was primarily due to cash used…
Fulcrum Therapeutics CFO Alan Musso to retire
CFO Alan Musso plans to retire later this year to spend more time with his family and other outside interests. Musso will remain in his role until a successor is…
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlu...
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve...
Fulcrum Therapeutics Slides: Corporate presentation
Fulcrum Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to imp...
Leerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update
Leerink thinks Agios Pharmaceuticals’ (AGIO) announcement that it is filing mitapivat for accelerated approval in sickle cell disease has positive readthrough to Fulcrum Therapeutics (FULC) by demonst...
Fulcrum Therapeutics enters partnership for emergency sickle cell disease care
Fulcrum Therapeutics (FULC), MedicAlert Foundation, a nonprofit providing medical IDs and emergency medical information services, and Sickle Cell Disease Association of America, or SCDAA, the national...
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis Three-year collaboration is aimed at enhancing a key aspect of sickle cell m...
Fulcrum Therapeutics Transcript: Leerink Global Healthcare Conference 2026
PIONEER study data showed strong HbF induction, VOC reduction, and a favorable safety profile, generating positive feedback and interest for future trials. The next step is a pivotal registrational study with interim analysis for accelerated approval, while business focus remains on sickle cell disease and U.S. commercialization.
Fulcrum Therapeutics Slides: Corporate presentation
Fulcrum Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 6, 2026.
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to imp...
Fulcrum Therapeutics price target lowered to $17 from $18 at Truist
Truist analyst Gregory Renza lowered the firm’s price target on Fulcrum Therapeutics (FULC) to $17 from $18 and keeps a Buy rating on the shares. The firm caught up with…
Fulcrum PIONEER data reinforce pociredir differentiated profile, Wainwright says
Keeping a Buy rating on Fulcrum Therapeutics (FULC), H.C. Wainwright views the full 12-week data from the 20 mg cohort of the PIONEER study as encouraging and supportive of pociredir’s…
Fulcrum Therapeutics move lower ‘overdone,’ says Stifel
Stifel analyst James Condulis tells investors that the move lower in Fulcrum Therapeutics (FULC) this morning “surprises us” and looks “overdone.” While the firm believes some thought total mean HbF…
Truist remain buyers of Fulcrum Therapeutics shares on weakness
After Fulcrum Therapeutics (FULC) disclosed full Cohort 4 data from the Phase Ib PIONEER study for pociredir in sickle cell disease, Truist notes that mean absolute HbF was 19.3% and…
Fulcrum Therapeutics Earnings Call Transcript: Q4 2025
The 20-mg cohort in the PIONEER trial showed robust HbF induction, improved anemia and hemolysis, and encouraging VOC reduction, with pociredir well-tolerated and poised for late-stage trials. Plans are underway for global expansion and regulatory engagement.
Fulcrum Therapeutics Annual report: Q4 2025
Fulcrum Therapeutics has published its Q4 2025 annual report on February 24, 2026.